Clinical TrialsSearch results
Number of results: 615
Other
- Z-206 Phase III Clinical Trial -Investigation on the remission–maintaining effect in patients with Crohn's disease in remission phase-
- Patients with Crohn's disease in remission phase
- Zeria Pharmaceutical Co.,LTD.
- 2005-12-22
Other
- Z-206 Phase III Clinical Trial - Investigation on the remission-maintaining effect in patients with ulcerative colitis in remission phase -
- Patients with ulcerative colitis in remission phase.
- Zeria Pharmaceutical Co.,LTD.
- 2005-11-21
Other
- Z-206 Phase III Clinical Trial - Investigation on the remission-inducing effect in patients with ulcerative colitis in active phase -
- Patients with ulcerative colitis in active phase
- Zeria Pharmaceutical Co.,LTD.
- 2005-11-21
Other
- Phase III study of Z-100 in uterine cervix cancer patients
- primary uterine cervix cancer
- ZERIA Pharmaceutical Co.,Ltd.
- 2005-09-13
Other
- Accelerative effect of polaprezinc on healing gastric ulcer after eradication of Helicobacter pylori infection
- Gastric ulcer with Helicobacter pylori infection
- Zeria Pharmaceutical Co.,LTD.
- 2005-09-13
Other
- Z-206 Phase III Clinical Trial - Investigation on the remission-inducing effect in patients with Crohn's disease in active phase -
- Patients with Crohn's disease in active phase
- Zeria Pharmaceutical Co.,LTD
- 2005-12-22
Other
- Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20
- Multiple myeloma expressing CD20
- Zenyaku Kogyo Co., Ltd.
- 2006-11-28
Other
- Phase II study of Rituximab in Patients with Systemic Lupus Erythematosus
- Systemic lupus erythematosus
- Zenyaku Kogyo Co., Ltd.
- 2007-07-05
Other
- A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III study of Rituximab in Patients with Systemic Lupus Erythematosus
- Systemic lupus erythematosus
- Zenyaku Kogyo Co., Ltd.
- 2007-03-16
Other
- A multicenter phase II open-label study in untreated patients with CD20 positive indolent B-cell non-Hodgkin's lymphoma evaluating efficacy and safety of maintenance therapy with IDEC-C2B8.
- Untreated patients with CD20 positive indolent B-cell non-Hodgkin's lymphoma.
- Zenyaku Kogyo Co., Ltd.
- 2008-12-26